【科伦博泰生物股价创新高 业界人士：企业盈利改善、资本信心回暖有望形成正向带动】金十数据2月26日讯，近日，港股创新药上市公司科伦博泰生物不断走高。除业绩因为一系列授权交易得到大幅改善外，去年年底至今，科伦博泰包括芦康沙妥珠单抗在内的三款药物已经获批上市。此外，科伦博泰股价近期上涨也与港股创新药板块行情修复有关。一位医药行业人士表示，国产创新药上市以及海外授权里程碑付款密集确认，提振了行业及资本信心。企业盈利能力改善、产业政策端支持以及科技板块整体热度的回归，共同带动了新药个股的股价表现。未来，创新药企业盈利能力改善和资本信心回暖有望形成正向带动效应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.